Cited by 245Pharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and ProtectionDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression

Abstract

The flavin-containing monooxygenases (FMOs) are important for the metabolism of numerous therapeutics and toxicants. Six mammalian FMO genes (FMO1-6) have been identified, each exhibiting developmental and tissue- and species-specific expression patterns. Previous studies demonstrated that human hepatic FMO1 is restricted to the fetus whereas FMO3 is the major adult isoform. These studies failed to describe temporal expression patterns, the precise timing of the FMO1/FMO3 switch, or potential control mechanisms. To address these questions, FMO1 and FMO3 were quantified in microsomal fractions from 240 human liver samples representing ages from 8 wk gestation to 18 y using Western blotting. FMO1 expression was highest in the embryo (8-15 wk gestation; 7.8 +/- 5.3 pmol/mg protein). Low levels of FMO3 expression also were detectable in the embryo, but not in the fetus. FMO1 suppression occurred within 3 d postpartum in a process tightly coupled to birth, but not gestational age. The onset of FMO3 expression was highly variable, with most individuals failing to express this isoform during the neonatal period. FMO3 was detectable in most individuals by 1-2 y of age and was expressed at intermediate levels until 11 y (12.7 +/- 8.0 pmol/mg protein). These data suggest that birth is necessary, but not sufficient for the onset of FMO3 expression. A gender-independent increase in FMO3 expression was observed from 11 to 18 y of age (26.9 +/- 8.6 pmol/mg protein). Finally, 2- to 20-fold interindividual variation in FMO1 and FMO3 protein levels were observed, depending on the age bracket.

Overview

Integrity signals

Registry

Crossref · 10.1203/00006450-200202000-00018

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 15

  1. Clement B, 1993, Drug Metab Dispos, 21, 24
  2. Cashman JR, 1993, Drug Metab Dispos, 21, 587
  3. Frederick CB, 1982, Cancer Res, 42, 2671
  4. Cashman JR, 1986, Mol Pharmacol, 29, 163
  5. Tynes RE, 1987, Mol Pharmacol, 31, 569
  6. Shehin-Johnson SE, 1995, J Pharmacol Exp Ther, 272, 1293
  7. Yeung CK, 2000, Drug Metab Dispos, 28, 1107
  8. Hines RN, 2001, Drug Metab Dispos, 29, 623
  9. Sadeque AJM, 1992, Drug Metab Dispos, 20, 832
  10. Duffel MW, 1981, Mol Pharmacol, 19, 134
  11. Yang H-YL, 1994, Mol Pharmacol, 46, 922
  12. Devereux TR, 1975, Drug Metab Dispos, 3, 254
  13. Larsen-Su S, 1996, Drug Metab Dispos, 24, 927
  14. Park C-S, 1999, Pharmacogenetics, 9, 155
  15. Zschocke J, 1999, Lancet, 354, 834

Cited by

Sorted by citations

See all 245

Metadata

Authors
Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E., & Hines, R. N.
Affiliations
  • Medical College of Wisconsin (US)
  • University of Arkansas for Medical Sciences (US)
  • University of Washington (US)
Corresponding author
Hines, Ronald N
Venue
Pediatric Research
Published
2002-02
Volume
51
Issue
2
Pages
236-243
ISSN
  • 0031-3998 (ISSN-L)
  • 1530-0447
OpenAlex
W2068390361
Cited by
245
References
66
Citations by year
2026: 4 · 2025: 5 · 2024: 6 · 2023: 11 · 2022: 5 · 2021: 9 · 2020: 12 · 2019: 11 · 2018: 6 · 2017: 13 · 2016: 15 · 2015: 2 · 2014: 14 · 2013: 8 · 2012: 17
FWCI
9.16
Type
journal article
Language
en
Open access
closed
Locations
  • Pediatric Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (CA53106, R01CA053106)
  • National Institute of General Medical Sciences (GM43511, GM-07750, T32GM007750)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
flavin-containing monooxygenase, FMO1, FMO3, developmental gene expression, fetal liver, neonatal liver, age-related expression, interindividual variability, human liver microsomes, drug metabolism
MeSH terms
Adolescent, Adult, Aging, Child, Child, Preschool, Embryo, Mammalian, Female, Fetus, Gestational Age, Humans, Infant, Infant, Newborn, Isoenzymes, Liver, Male, Microsomes, Liver, Oxygenases, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Developmental

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review